Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab for Prevention of Recurrent Acute Pancreatitis in Severe Hypertriglyceridemia
NCT04863014Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of evinacumab in hypertriglyceridemia, sponsored by Regeneron Pharmaceuticals. Started Jul 2021; status: terminated.
02
Drugs
evinacumab
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04863014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863014.